A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy

BACKGROUND: In a randomized study, glasdegib (a hedgehog inhibitor) plus low‐dose cytarabine (LDAC) significantly prolonged survival in comparison with LDAC in patients with acute myeloid leukemia (AML). A quality‐adjusted time without symptoms of disease progression or toxicity (Q‐TWiST) approach w...

Descripción completa

Detalles Bibliográficos
Autores principales: Solem, Caitlyn T., Bell, Timothy J., Kwon, Youngmin, Cappelleri, Joseph C., Johnson, Courtney, Bhattacharyya, Helen, Hoang, Caroline J., Cortes, Jorge E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540307/
https://www.ncbi.nlm.nih.gov/pubmed/32697335
http://dx.doi.org/10.1002/cncr.33072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540307/
https://www.ncbi.nlm.nih.gov/pubmed/32697335
http://dx.doi.org/10.1002/cncr.33072

Ejemplares similares